Bojangles Introduces Watermelon Sweet Tea to Kick off Summer
CHARLOTTE, N.C.--(BUSINESS WIRE)--As the weather heats up, Bojangles is putting a fresh twist on its iconic beverage with the launch of Watermelon Sweet Tea. This limited-time offering blends our Legendary Iced Tea®, steeped the old-fashion way, with real watermelon juice for a new, refreshing flavor perfect for the summer season. Watermelon Sweet Tea is ideal for on-the-go summer road trips, afternoon pick-me-ups or pairing with your favorite Bojangles treats.
To celebrate the launch – and the excitement of the PGA Championship in Bojangles' hometown of Charlotte – fans everywhere can enjoy a free Watermelon Sweet Tea at participating locations from May 15–22 by using the promo code TEATIME at checkout. It's a sweet way to kick off summer and toast one of golf's biggest events.
To mark the occasion, the chain hosted a 'Tea Time' event in Charlotte, where guests enjoyed golf games, giveaways and free Watermelon Sweet Tea. PGA TOUR golfer Chesson Hadley was also onsite for a meet-and-greet to celebrate the new menu item. Photos from the event are linked here.
'Our Legendary Iced Tea pairs beautifully with the unique flavors of our food, so we decided to add a juicy twist to an already iconic Southern beverage,' said Marshall Scarborough, VP of Menu & Culinary Innovation at Bojangles. 'Our Watermelon Sweet Tea blends refreshing watermelon juice with our tea for a light and fresh taste while still delivering that legendary experience our fans know and love.'
Bojangles encourages fans to visit their local restaurant to pair the new drink with other limited-time, seasonal favorites like Bo-Berry Cookies and Sausage Bo-Berry Biscuits. For those on the go, Watermelon Sweet Tea is also available for delivery or pickup through the Bojangles app.
About Bojangles, Inc.
Bojangles is a Carolina-born restaurant chain specializing in breakfast and Southern-style chicken, biscuits and tea all made from scratch. Founded in 1977 as a single location in Charlotte, the beloved brand has grown to more than 800 company-owned and franchised restaurants in 18 states. For more information about Bojangles' handcrafted approach to food and community impact, visit www.bojangles.com. To join in on the fan fun, follow Bojangles on Instagram, TikTok and Twitter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
30 minutes ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Sign in to access your portfolio
USA Today
4 hours ago
- USA Today
2025 LIV Golf Virginia prize money payouts for each LIV Golf player at Robert Trent Jones Golf Club
2025 LIV Golf Virginia prize money payouts for each LIV Golf player at Robert Trent Jones Golf Club LIV Golf is Joaquin Niemann's world, everyone else is just living in it. The Chilean secured his fourth victory this year in eight LIV Golf events, taking the individual title Sunday at LIV Golf Virginia by a shot over Graeme McDowell. He heads to the U.S. Open having won three of his past five LIV Golf starts and coming off his best finish in a major yet, a T-8 finish in the PGA Championship at Quail Hollow. With the win, Niemann takes home $4 million of the $20 million purse. Meanwhile, Bryson DeChambeau's Crushers GC earned the team title for the second straight event and will split the $3 million that comes with it. Here's the breakdown of how much money each player and team earned at 2025 LIV Golf Virginia. LIV Golf Virginia 2025 prize money payouts Position Player Score Earnings 1 Joaquin Niemann -15 $4,000,000 T2 Graeme McDowell -14 $1,875,000 T2 Anirban Lahiri -14 $1,875,000 T4 Thomas Pieters -13 $775,000 T4 Bryson DeChambeau -13 $775,000 T4 Phil Mickelson -13 $775,000 T4 Bubba Watson -13 $775,000 T8 Jon Rahm -10 $483,750 T8 Martin Kaymer -10 $483,750 T10 Talor Gooch -9 $361,000 T10 Lee Westwood -9 $361,000 T10 Marc Leishman -9 $361,000 T10 Carlos Ortiz -9 $361,000 T10 Dustin Johnson -9 $361,000 T15 Brendan Steele -8 $285,000 T15 Sebastian Munoz -8 $285,000 T15 Tyrrell Hatton -8 $285,000 18 Harold Varner III -7 $270,000 T19 Paul Casey -6 $235,000 T19 Branden Grace -6 $235,000 T19 Ben Campbell -6 $235,000 T19 Abraham Ancer -6 $235,000 T23 Jason Kokrak -5 $193,333 T23 Louis Oosthuizen -5 $193,333 T23 Patrick Reed -5 $193,333 T23 Dean Burmester -5 $193,333 T23 Cameron Smith -5 $193,333 T23 Jinichiro Kozuma -5 $193,333 T29 Cameron Tringale -4 $167,500 T29 Charl Schwartzel -4 $167,500 T29 Richard Bland -4 $167,500 T29 Adrian Meronk -4 $167,500 T33 Brooks Koepka -3 $148,200 T33 Charles Howell III -3 $148,200 T33 Peter Uihlein -3 $148,200 T33 Sam Horsfield -3 $148,200 T33 Luis Masaveu -3 $148,200 T38 Sergio Garcia -2 $136,500 T38 Kevin Na -2 $136,500 T38 Yubin Jang -2 $136,500 T38 Tom McKibbin -2 $136,500 42 Caleb Surratt -1 $130,000 43 Danny Lee 1 $128,000 T44 Anthony Kim 2 $126,500 T44 Henrik Stenson 2 $126,500 46 Lucas Herbert 3 $125,000 T47 Frederik Kjettrup 4 $121,500 T47 Ian Poulter 4 $121,500 49 Andy Ogletree 6 $60,000 T50 Miro Pereira 7 $56,667 T50 Matt Jones 7 $56,667 T50 Josele Ballester 7 $56,667 53 Max Lee 11 $50,000 LIV Golf Virginia 2025 team prize money payouts
